Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

Sickle Cell Disease Gene Therapy Receives Orphan Drug Designation

ARU-1801, an investigational gene therapy for the treatment of sickle cell disease (SCD) and beta thalassemia, was granted orphan drug designation by the FDA. ARU-1801...

BioMarin Sets High Price Tag for Hemophilia Gene Therapy Candidate

If its experimental gene therapy for patients with hemophilia A is approved by the FDA, BioMarin Pharmaceutical is considering pricing valoctocogene roxaparvovec (valrox) between...

FDA Approves Ferric Derisomaltose for Iron-Deficiency Anemia

The ferric derisomaltose injection received FDA approval for the treatment of iron-deficiency anemia in adults who are intolerant to oral iron, whose disease has...

Treatment for Lymphoplasmacytic Lymphoma Receives Orphan Designation

The FDA granted orphan drug designation to CLR 131, a phospholipid-drug conjugate that selectively delivers the radioisotope iodine-131 to tumor cells. CLR 131 is being...

FDA Places Partial Hold on Clinical Trials of Lacutamab for Advanced T-Cell Lymphomas

The FDA has placed a partial clinical hold on the phase II TELLOMAK trial, which is evaluating the safety and efficacy of lacutamab in...

Drug Prices Increase by an Average of 5.8% for 2020

On January 1, 2020, more than 60 pharmaceutical companies raised list prices on hundreds of medications by an average of 5.8%. Nearly all price...

Study Finds Hospital Mergers Failed to Improve Quality of Care

Research published in the New England Journal of Medicine found that the recent wave of health care mergers and acquisitions had no substantial impact...

Acalabrutinib Approved for CLL Under New International Collaboration

The FDA granted a supplemental approval to acalabrutinib for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Acalabrutinib...

Bristol-Myers Wins $752 Million From Gilead in Patent Dispute

Bristol-Myers Squibb has won a $752 million lawsuit against Gilead Sciences to settle a U.S. patent dispute regarding the chimeric antigen receptor (CAR) T-cell...

FDA Approves Voxelotor for Sickle Cell Disease

The FDA has approved voxelotor, a once-daily oral therapy that modulates hemoglobin affinity for oxygen by binding to hemoglobin S and stabilizing it, to...
Advertisement

Current Issue

May 2020, Volume 6, Issue 6

This issue discusses AI's potential to improve patient care, debates using donors with clonal hematopoiesis for alloHCT, and more.